Henry Osei, MD
Internal Medicine · Las Vegas, NVNPI 1235102716
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Boehringer Ingelheim at 33.1% of the total. Reporting peaked in 2022 at $142 and has fallen 89.5% since, to $15 in 2024. That places this record below the midpoint for internal medicine clinicians in NV, where the typical reported total is $253.
Across 15 payments — averaging $15.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$78
- AstraZeneca$32
- Biohaven Pharmaceutical Holding Company Ltd.$30
- Johnson & Johnson$28
- Novartis$19
- Amarin Pharma, Inc.$19
- plus $32 from 2 others
What the payments were for
- Food & beverage$237100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 5 | $78 |
| AstraZeneca | 2 | $32 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $30 |
| Johnson & Johnson | 2 | $28 |
| Novartis | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $19 |
| Novo Nordisk | 1 | $17 |
| Abbott | 1 | $15 |
How this compares
$237 in reported general payments places this provider in the 45th percentile of 1,071 internal medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 18 | $21,673 |
| Atorvastatin Calcium | 127 | $1,449 |
| Tamsulosin Hcl | 53 | $1,052 |
| Levothyroxine Sodium | 103 | $952 |
| SynthroidLevothyroxine Sodium | 21 | $926 |
| Rosuvastatin Calcium | 51 | $851 |
| Omeprazole | 47 | $827 |
| Losartan Potassium | 65 | $822 |
| Amlodipine Besylate | 119 | $810 |
| Celecoxib | 13 | $615 |
| Gabapentin | 35 | $512 |
| Potassium Chloride | 30 | $455 |
| Pantoprazole Sodium | 23 | $435 |
| Lisinopril | 61 | $431 |
| Glipizide ErGlipizide | 22 | $374 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Las Vegas
- Kevin DunsmoorLas Vegas$241K
- Robert ChiascioneLas Vegas$174K
- Dino GonzalezLas Vegas$126K
- Rosanne SugayLas Vegas$63K
- Chad HallLas Vegas$42K
- Zubin DamaniaLas Vegas$40K
- Audrey Sue CruzLas Vegas$34K
- Bashab BanerjiLas Vegas$26K
- Amaan ShafiLas Vegas$25K
- Sassan KavehLas Vegas$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.